Knight Therapeutics (KHTRF) has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement entered with Paladin Pharma. On the closing date, Knight paid approximately $107 million in cash including $22.3 million for the payment of inventory. The payment at closing was reduced by a holdback amount of $15.4 million, of which $10 million may be released under specific conditions and the remaining $5.4 million is expected to be used to settle certain liabilities. In addition, Knight may pay future contingent payments of up to US$15 million upon achieving certain sales milestones.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth
- Knight Therapeutics closes $50M revolving credit facility
- Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal
- Knight Therapeutics’ Earnings Call: Growth Amid Challenges
- Knight Therapeutics: Strong Buy Rating Amid Promising Financial Outlook and Strategic Resilience